| Business Summary | | Boston
Biomedica,
Inc.
and
its
wholly
owned
subsidiaries
provide
products
and
services
for
the
detection
and
treatment
of
infectious
diseases
such
as
AIDS
and
Viral
Hepatitis.
As
of
March
1,
2001,
the
Company
had
three
business
units:
BBI
Diagnostics,
a
manufacturer
of
quality
control
and
other
diagnostic
products
used
to
increase
the
accuracy
of
in
vitro
diagnostic
tests;
BBI
Biotech
Research
Laboratories,
the
research
and
development
arm
of
the
Company,
which
supplements
its
support
for
the
other
BBI
business
units
with
research
contracts
and
repository
services
primarily
for
agencies
of
the
United
States
government;
and
BBI
Source
Scientific,
a
manufacturer
of
laboratory
and
medical
instruments. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Boston
Biomedica,
Inc.
is
a
provider
of
proprietary
quality
control
products
for
use
with
in
vitro
diagnostic
test
kits
for
the
detection,
analysis
and
monitoring
of
infectious
diseases.
For
the
six
months
ended
6/01,
revenues
rose
4%
to
$10.5
million.
Net
loss
from
continuing
operations
fell
49%
to
$449
thousand.
Results
reflect
increased
sales
in
the
Laboratory
Instrumentation
segment,
higher
repository
service
revenues
and
a
reduction
in
interest
and
administrative
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Richard Schumacher, 50 Chairman
and CEO | $236K | $288K | Kevin Quinlan, 51 Pres,
COO | 183K | -- | Patricia Garrett, Ph. D., 57 Sr.
VP - Strategic Programs | 128K | 68K | Mark Manak, Ph. D., 49 Sr.
VP and Gen. Mang. of BBI Biotech | 138K | -- | David Petersen, 54 Sr.
VP and Gen. Mang. of BBI Source | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|